Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Geron Bio-Med Ltd.

Division of Geron Corp.

Latest From Geron Bio-Med Ltd.

Ardana Bioscience Ltd.

A recent spin-off from the UK's government-funded Medical Research Council, Ardana Bioscience Ltd. has been set up to commercialize research into women's health. On its agenda are new products for underserved areas such as menstrual disorders and endometriosis; more convenient contraceptive drugs--including the male pill--and a product to ease childbirth. Rather than commercializing a specific patented technology, like most spin-offs, the company has the option to acquire rights to any technology generated by the MRC's Human Reproductive Sciences Unit in Edinburgh over the next five years.
BioPharmaceutical Strategy

Rewriting Fate: The Stem Cell Transplant Business

Physicians, patients, and companies can now see the stem cell transplant business taking shape. Stem cell trials are finally in progress, allowing investors and corporate partners to finally see just how effective this multi-billion-dollar opportunity to replace many highly problematic organ transplants, and dramatically expand the procedures into new areas, can be. Beyond the lack of clinical conformation, stem cell transplantation therapy has been held back by the inability to culture large quantities of cells--as with whole organ transplants, there simply isn't enough tissue to go around. For the most part, companies have had to propose autologous transplantation strategies or, at best, transplants from one donor for just a few patients--an economically difficult-to-justify business. Geron, the only player in this group to have benefited from the last nine months of biotech stock mania, holds a key competitive advantage: its ability to use embryonic stem cells (ESCs) to create, theoretically, nearly infinite quantities of any cell in the body. But recent developments have stirred the competitive pot: a number of companies have created methods for growing enough adult stem cells to provide them to significant numbers of patients. Meanwhile, researchers have transformed fully committed adult stem cells into cells of different lineages, raising the possibility that alternatives to ESCs for tissue replacement or repair exist. The transplant replacement business--regenerative medicine--has caught the public's attention. Nonetheless, the stem cell industry has remained a start-up's trade, and it's easy to see why: large-company experiences in the area have not, for the most part, been happy ones, as companies face the issues of installing unpharma-like infrastructures to deliver personalized therapy, as well as ethical concerns, which must be given appropriate consideration. But these and other hurdles shouldn't obscure the growing opportunity. Stem cell therapy, so long a therapeutic chimera, now seems ripe for commercial exploitation.
BioPharmaceutical Platform Technologies

Roslin Bio-Med Ltd.

Can Dolly the sheep bring home the bacon? Roslin Bio-Med has licensed nuclear transfer technology from the Roslin Institute to develop transgenic pigs from which the start-up hopes to obtain organs for transplant and blood products.

British Start-Ups

Many think that British biotech is a disaster waiting to happen. The four companies profiled in this issue are attempting to establish themselves as product-driven companies, run by professional managers.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Roslin Bio-Med Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Geron Corp.
  • Senior Management
  • Simon G Best, CEO
    Ian Biggs, CFO
    Ian Kent, Chmn.
    Ian Wilmut, R&D
    Lincoln Pies, Bus. Dev.
  • Contact Info
  • Geron Bio-Med Ltd.
    Phone: (44) 131527427
    Roslin Biotechnology Centre
    Mid-Lothian, EH25 9PS